芬戈莫德治疗下的复发性肿胀性脱髓鞘病变。 - Suppr

Recurrent tumefactive demyelination under fingolimod treatment.

作者信息

İriş Merve, Kızılkılıç Osman, Saip Sabahattin, Uygunoğlu Uğur

机构信息

Department of Neurology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Kocamustafapaşa Street No:53 Cerrahpaşa, 34098, Fatih/Istanbul, Turkey.

Division of Neuroradiology, Department of Radiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

出版信息

Neurol Sci. 2024 May;45(5):2377-2378. doi: 10.1007/s10072-024-07310-4. Epub 2024 Jan 15.

DOI:10.1007/s10072-024-07310-4

PMID:38221541

Abstract

摘要

相似文献

Recurrent tumefactive demyelination under fingolimod treatment.

Neurol Sci. 2024 May;45(5):2377-2378. doi: 10.1007/s10072-024-07310-4. Epub 2024 Jan 15.

Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.

Mult Scler Relat Disord. 2015 Sep;4(5):400-402. doi: 10.1016/j.msard.2015.05.007. Epub 2015 May 22.

[A case of multiple sclerosis with a tumefactive lesion during long-term treatment with fingolimod, leading to decompressive craniotomy].

Rinsho Shinkeigaku. 2023 Jan 28;63(1):37-44. doi: 10.5692/clinicalneurol.cn-001806. Epub 2022 Dec 24.

Re-emergence of a tumefactive demyelinating lesion after initiation of fingolimod therapy.

J Neurol Sci. 2017 Aug 15;379:167-168. doi: 10.1016/j.jns.2017.06.002. Epub 2017 Jun 7.

Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.

Acta Neurol Belg. 2017 Dec;117(4):821-827. doi: 10.1007/s13760-017-0794-7. Epub 2017 May 20.

Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.

Mult Scler. 2021 May;27(6):903-912. doi: 10.1177/1352458520938354. Epub 2020 Jul 14.

Tumefactive demyelinating lesions: A comprehensive review.

Mult Scler Relat Disord. 2017 May;14:72-79. doi: 10.1016/j.msard.2017.04.003. Epub 2017 Apr 9.

Fingolimod-Associated Intracerebral Lymphoproliferative Disorder.

Am J Ther. 2019 Jul/Aug;26(4):e481-e484. doi: 10.1097/MJT.0000000000000694.

Glioblastoma in a fingolimod-treated multiple sclerosis patient: Causal or coincidental association?

Mult Scler Relat Disord. 2020 Jun;41:102012. doi: 10.1016/j.msard.2020.102012. Epub 2020 Feb 15.

Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.

Neurol Neurochir Pol. 2017 Mar-Apr;51(2):156-162. doi: 10.1016/j.pjnns.2017.01.006. Epub 2017 Feb 2.

引用本文的文献

CNS Resident Innate Immune Cells: Guardians of CNS Homeostasis.

Int J Mol Sci. 2024 Apr 29;25(9):4865. doi: 10.3390/ijms25094865.

本文引用的文献

Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.

Front Neurol. 2022 Mar 15;13:868525. doi: 10.3389/fneur.2022.868525. eCollection 2022.

Quantifying the Metabolic Signature of Multiple Sclerosis by Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker.

Front Neurol. 2019 Nov 15;10:1173. doi: 10.3389/fneur.2019.01173. eCollection 2019.

Tumefactive MS lesions under fingolimod: a case report and literature review.

Neurology. 2013 Nov 5;81(19):1654-8. doi: 10.1212/01.wnl.0000435293.34351.11. Epub 2013 Oct 4.

Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions.

AJNR Am J Neuroradiol. 2014 Feb;35(2):270-7. doi: 10.3174/ajnr.A3677. Epub 2013 Aug 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Recurrent tumefactive demyelination under fingolimod treatment.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献